Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease DOI Creative Commons
Magdalini Kreouzi, Nikolaos Theodorakis, Maria Nikolaou

и другие.

Microorganisms, Год журнала: 2025, Номер 13(1), С. 161 - 161

Опубликована: Янв. 14, 2025

Metabolic disorders, including type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome, are systemic conditions that profoundly impact the skin microbiota, a dynamic community of bacteria, fungi, viruses, mites essential for cutaneous health. Dysbiosis caused by dysfunction contributes to barrier disruption, immune dysregulation, increased susceptibility inflammatory diseases, psoriasis, atopic dermatitis, acne. For instance, hyperglycemia in T2DM leads formation advanced glycation end products (AGEs), which bind receptor AGEs (RAGE) on keratinocytes cells, promoting oxidative stress inflammation while facilitating Staphylococcus aureus colonization dermatitis. Similarly, obesity-induced dysregulation sebaceous lipid composition increases saturated fatty acids, favoring pathogenic strains Cutibacterium acnes, produce metabolites exacerbate Advances metabolomics microbiome sequencing have unveiled critical biomarkers, such as short-chain acids microbial signatures, predictive therapeutic outcomes. example, elevated butyrate levels psoriasis been associated with reduced Th17-mediated inflammation, presence specific Lactobacillus has shown potential modulate tolerance Furthermore, machine learning models increasingly used integrate multi-omics data, enabling personalized interventions. Emerging therapies, probiotics postbiotics, aim restore diversity, phage therapy selectively targets bacteria like without disrupting beneficial flora. Clinical trials demonstrated significant reductions lesions improved quality-of-life metrics patients receiving these microbiota-targeted treatments. This review synthesizes current evidence bidirectional interplay between disorders highlighting implications future directions. By addressing microbiota-mediated pathways, precision strategies paving way patient outcomes dermatologic care.

Язык: Английский

Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease DOI Creative Commons
Magdalini Kreouzi, Nikolaos Theodorakis, Maria Nikolaou

и другие.

Microorganisms, Год журнала: 2025, Номер 13(1), С. 161 - 161

Опубликована: Янв. 14, 2025

Metabolic disorders, including type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome, are systemic conditions that profoundly impact the skin microbiota, a dynamic community of bacteria, fungi, viruses, mites essential for cutaneous health. Dysbiosis caused by dysfunction contributes to barrier disruption, immune dysregulation, increased susceptibility inflammatory diseases, psoriasis, atopic dermatitis, acne. For instance, hyperglycemia in T2DM leads formation advanced glycation end products (AGEs), which bind receptor AGEs (RAGE) on keratinocytes cells, promoting oxidative stress inflammation while facilitating Staphylococcus aureus colonization dermatitis. Similarly, obesity-induced dysregulation sebaceous lipid composition increases saturated fatty acids, favoring pathogenic strains Cutibacterium acnes, produce metabolites exacerbate Advances metabolomics microbiome sequencing have unveiled critical biomarkers, such as short-chain acids microbial signatures, predictive therapeutic outcomes. example, elevated butyrate levels psoriasis been associated with reduced Th17-mediated inflammation, presence specific Lactobacillus has shown potential modulate tolerance Furthermore, machine learning models increasingly used integrate multi-omics data, enabling personalized interventions. Emerging therapies, probiotics postbiotics, aim restore diversity, phage therapy selectively targets bacteria like without disrupting beneficial flora. Clinical trials demonstrated significant reductions lesions improved quality-of-life metrics patients receiving these microbiota-targeted treatments. This review synthesizes current evidence bidirectional interplay between disorders highlighting implications future directions. By addressing microbiota-mediated pathways, precision strategies paving way patient outcomes dermatologic care.

Язык: Английский

Процитировано

0